# Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)

> **NCT02568267** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Hoffmann-La Roche** · enrollment: 534 (actual)

## Conditions studied

- Breast Cancer
- Cholangiocarcinoma
- Colorectal Cancer
- Head and Neck Neoplasms
- Lymphoma, Large-Cell, Anaplastic
- Melanoma
- Neuroendocrine Tumors
- Non-Small Cell Lung Cancer
- Ovarian Cancer
- Pancreatic Cancer
- Papillary Thyroid Cancer
- Primary Brain Tumors
- Renal Cell Carcinoma
- Sarcomas
- Salivary Gland Cancers
- Adult Solid Tumor

## Interventions

- **DRUG:** Entrectinib

## Key facts

- **NCT ID:** NCT02568267
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2015-11-19
- **Primary completion:** 2026-05-14
- **Final completion:** 2026-05-14
- **Target enrollment:** 534 (ACTUAL)
- **Last updated:** 2026-03-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02568267

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02568267, "Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02568267. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*